Crystal Structure of PI3Kgamma with a Dihydropurinone Inhibitor

AstraZeneca (Poland) researcher J. Petersen contributed this dataset describing the crystal structure of PI3Kgamma bound to a dihydropurinone inhibitor (compound 4). The description indicates the inhibitor showed monotherapy activity in murine xenograft models and regressions when combined with DNA damage inducers or PARP inhibition. These data supported progression into a clinical study identified as NCT03907969.

Use Cases

• Predicting inhibitor binding affinity based on the described crystal structure.
• Analyzing kinase selectivity profiles based on the described off-target activity against the protein kinome.
• Modeling combination therapy efficacy based on described interactions with DNA damage inducers or PARP inhibitors.

Strengths

• Data is linked to a specific clinical trial (NCT03907969), providing a research anchor.
• Description includes specific biological activity results (monotherapy in murine models, combination regressions).

Limitations

• Row count and file format are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

AstraZeneca (Poland)

Collection Method

Likely generated from X-ray crystallography and preclinical pharmacological studies.